| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Yuedi Ding, Jun Fan, Wenxin Li, Ying Peng, Runlin Yang, Lili Deng, Qiang F. The effect of albumin fusion structure on the production and bioactivity of the somatostatin-28 fusion protein in Pichia pastoris. Journal of industrial microbiology & biotechnology. vol 41. issue 6. 2014-09-11. PMID:24752560. |
somatostatin, a natural inhibitor of growth hormone (gh), and its analogs have been used in clinical settings for the treatment of acromegaly, gigantism, thyrotropinoma, and other carcinoid syndromes. |
2014-09-11 |
2023-08-13 |
Not clear |
| Roberto Salvatori, Whitney W Woodmansee, Mark Molitch, Murray B Gordon, Kathleen G Loma. Lanreotide extended-release aqueous-gel formulation, injected by patient, partner or healthcare provider in patients with acromegaly in the United States: 1-year data from the SODA registry. Pituitary. vol 17. issue 1. 2014-09-02. PMID:23314980. |
baseline data include patient demographics, previous acromegaly treatment and investigations, gh and igf-i levels, ld dose and dose adjustment frequency. |
2014-09-02 |
2023-08-12 |
Not clear |
| Orsalia Alexopoulou, Marie Bex, Peter Kamenicky, Augustine Bessomo Mvoula, Philippe Chanson, Dominique Maite. Prevalence and risk factors of impaired glucose tolerance and diabetes mellitus at diagnosis of acromegaly: a study in 148 patients. Pituitary. vol 17. issue 1. 2014-09-02. PMID:23446424. |
impaired glucose metabolism is present in more than 50 % of patients at diagnosis of acromegaly, and is associated with an older age, a higher bmi, a family history of diabetes and a higher igf-i z-score, but not with fasting or post-ogtt gh levels. |
2014-09-02 |
2023-08-12 |
Not clear |
| Sang Ouk Chin, Suk Chon, You-Cheol Hwang, In-Kyung Jeong, Seungjoon Oh, Sung-Woon Ki. Change in somatostatinergic tone of acromegalic patients according to the size of growth hormone-producing pituitary tumors. Journal of Korean medical science. vol 28. issue 12. 2014-08-26. PMID:24339708. |
gh levels of 29 patients with newly diagnosed acromegaly were measured using a 75-gram oral glucose tolerance test (ogtt), an insulin tolerance test (itt), and an octreotide suppression test (ost). |
2014-08-26 |
2023-08-12 |
Not clear |
| Laura Chinezu, Emmanuel Jouanneau, Alexandre Vasiljevic, Jacqueline Trouillas, Gérald Ravero. Silent GH pituitary tumor: diagnostic and therapeutic challenges. Annales d'endocrinologie. vol 74. issue 5-6. 2014-08-24. PMID:24262981. |
silent gh pituitary tumors are characterized by the absence of clinical features of acromegaly, normal to slightly elevated gh and/or igf-1 levels, as well as immunohistochemical expression of gh. |
2014-08-24 |
2023-08-12 |
Not clear |
| Marilda Mormando, Luigi A Nasto, Antonio Bianchi, Gherardo Mazziotti, Antonella Giampietro, Enrico Pola, Alfredo Pontecorvi, Andrea Giustina, Laura De Marini. GH receptor isoforms and skeletal fragility in acromegaly. European journal of endocrinology. vol 171. issue 2. 2014-08-11. PMID:24866575. |
gh receptor isoforms and skeletal fragility in acromegaly. |
2014-08-11 |
2023-08-13 |
Not clear |
| Marilda Mormando, Luigi A Nasto, Antonio Bianchi, Gherardo Mazziotti, Antonella Giampietro, Enrico Pola, Alfredo Pontecorvi, Andrea Giustina, Laura De Marini. GH receptor isoforms and skeletal fragility in acromegaly. European journal of endocrinology. vol 171. issue 2. 2014-08-11. PMID:24866575. |
acromegaly is associated with an increased prevalence of vertebral fractures (vfs) in close relationship with gh hypersecretion. |
2014-08-11 |
2023-08-13 |
Not clear |
| Annamaria Colao, Silvia Vandeva, Rosario Pivonello, Ludovica Francesca Stella Grasso, Emil Nachev, Renata S Auriemma, Krasimir Kalinov, Sabina Zachariev. Could different treatment approaches in acromegaly influence life expectancy? A comparative study between Bulgaria and Campania (Italy). European journal of endocrinology. vol 171. issue 2. 2014-08-11. PMID:24878680. |
mortality in acromegaly strictly depends on optimal control of gh and igf1 levels. |
2014-08-11 |
2023-08-13 |
Not clear |
| Annamaria Colao, Silvia Vandeva, Rosario Pivonello, Ludovica Francesca Stella Grasso, Emil Nachev, Renata S Auriemma, Krasimir Kalinov, Sabina Zachariev. Could different treatment approaches in acromegaly influence life expectancy? A comparative study between Bulgaria and Campania (Italy). European journal of endocrinology. vol 171. issue 2. 2014-08-11. PMID:24878680. |
this retrospective, comparative, cohort study investigated the impact of different treatment modalities on disease control (gh and igf1) and mortality in acromegaly patients. |
2014-08-11 |
2023-08-13 |
Not clear |
| Nicholas A Tritos, Gudmundur Johannsson, Márta Korbonits, Karen K Miller, Ulla Feldt-Rasmussen, Kevin C J Yuen, Donna King, Anders F Mattsson, Peter J Jonsson, Maria Koltowska-Haggstrom, Anne Klibanski, Beverly M K Bille. Effects of long-term growth hormone replacement in adults with growth hormone deficiency following cure of acromegaly: a KIMS analysis. The Journal of clinical endocrinology and metabolism. vol 99. issue 6. 2014-08-08. PMID:24694339. |
gh deficiency (ghd) may occur in adults with cured acromegaly (acroghd). |
2014-08-08 |
2023-08-13 |
Not clear |
| Thomas J Wilson, Erin L McKean, Ariel L Barkan, William F Chandler, Stephen E Sulliva. Repeat endoscopic transsphenoidal surgery for acromegaly: remission and complications. Pituitary. vol 16. issue 4. 2014-07-29. PMID:23307479. |
retrospective chart review was undertaken to determine all patients having acromegaly with persistently elevated gh and/or igf-1 levels after initial pituitary adenoma resection, and who underwent reoperation using endoscopic endonasal approach at a single institution. |
2014-07-29 |
2023-08-12 |
Not clear |
| Michael Madsen, Sanne Fisker, Ulla Feldt-Rasmussen, Mikkel Andreassen, Lars Østergaard Kristensen, Hans Ørskov, Jens Otto L Jørgense. Circulating levels of pegvisomant and endogenous growth hormone during prolonged pegvisomant therapy in patients with acromegaly. Clinical endocrinology. vol 80. issue 1. 2014-07-29. PMID:23650996. |
to investigate whether pegvisomant treatment in acromegaly induces gradual elevations in endogenous serum growth hormone (gh) levels and whether serum pegvisomant levels predict the therapeutic outcome. |
2014-07-29 |
2023-08-12 |
Not clear |
| Kazutaka Ozeki, Yoshihisa Morishita, Sigeki Saito, Koji Umemura, Yohei Yamaguchi, Shotaro Tatekawa, Koichi Watamoto, Akio Kohno, Tsuyoshi Nogimor. Acute myeloid leukemia and colon carcinoma during the course of acromegaly. International journal of hematology. vol 98. issue 5. 2014-07-25. PMID:24061773. |
acromegaly is a rare disorder caused by excessive amounts of growth hormone (gh) primarily secreted by pituitary adenomas. |
2014-07-25 |
2023-08-12 |
Not clear |
| John D Carmichael, Vivien S Bonert, Miriam Nuño, Diana Ly, Shlomo Melme. Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis. The Journal of clinical endocrinology and metabolism. vol 99. issue 5. 2014-07-10. PMID:24606084. |
biochemical efficacy of somatostatin receptor ligand (srl) treatment in acromegaly is defined by metrics for gh and igf-1 control. |
2014-07-10 |
2023-08-12 |
Not clear |
| Jae Won Hong, Cheol Ryong Ku, Sun Ho Kim, Eun Jig Le. Characteristics of acromegaly in Korea with a literature review. Endocrinology and metabolism (Seoul, Korea). vol 28. issue 3. 2014-06-24. PMID:24396674. |
acromegaly is a slowly progressive disease caused by excessive growth hormone (gh), which is related to a gh secreting pituitary tumor in most cases. |
2014-06-24 |
2023-08-12 |
Not clear |
| Ji-Wen Wang, Ying Li, Zhi-Gang Mao, Bin Hu, Xiao-Bing Jiang, Bing-Bing Song, Xin Wang, Yong-Hong Zhu, Hai-Jun Wan. Clinical applications of somatostatin analogs for growth hormone-secreting pituitary adenomas. Patient preference and adherence. vol 8. 2014-06-24. PMID:24421637. |
excessive growth hormone (gh) is usually secreted by gh-secreting pituitary adenomas and causes gigantism in juveniles or acromegaly in adults. |
2014-06-24 |
2023-08-12 |
Not clear |
| Said Azzoug, Farida Chentl. Diabetic retinopathy in acromegaly. Indian journal of endocrinology and metabolism. vol 18. issue 3. 2014-06-19. PMID:24944939. |
our aim was to study its prevalence in subjects with acromegaly suffering from diabetes mellitus (dm), to analyze its characteristics, and to look for predictive factors such as age at diagnosis, gh concentration and duration, dm duration, dm control, and family background. |
2014-06-19 |
2023-08-13 |
human |
| Andrea Giustina, Ioannis Karamouzis, Ilaria Patelli, Gherardo Mazziott. Octreotide for acromegaly treatment: a reappraisal. Expert opinion on pharmacotherapy. vol 14. issue 17. 2014-06-10. PMID:24124691. |
acromegaly is a rare disorder characterized by excess secretion of growth hormone (gh) generally caused by a pituitary macroadenoma and associated with reduced life expectancy if the disease is untreated. |
2014-06-10 |
2023-08-12 |
Not clear |
| Ahmet Ozkok, Esra Hatipoglu, Nevbahar Tamcelik, Burcu Balta, Ahmet Sadi Gundogdu, Mehmet Akif Ozdamar, Pinar Kadiogl. Corneal biomechanical properties of patients with acromegaly. The British journal of ophthalmology. vol 98. issue 5. 2014-06-10. PMID:24489375. |
growth hormone (gh) and insulin-like growth factor-1 (igf-1) excess in acromegaly have various effects on many organs. |
2014-06-10 |
2023-08-12 |
human |
| C Mumby, J R E Davis, J Trouillas, C E Higha. Phaeochromocytoma and Acromegaly: a unifying diagnosis. Endocrinology, diabetes & metabolism case reports. vol 2014. 2014-06-06. PMID:24897038. |
growth hormone (gh) nadir on oral glucose tolerance test (ogtt) was 2.2 ng/ml with an elevated igf1 level of 435 ng/ml (72-215), confirming acromegaly biochemically. |
2014-06-06 |
2023-08-13 |
Not clear |